Alembic Limited is a diversified Indian enterprise undergoing a strategic pivot toward high-growth **Real Estate** development while maintaining a legacy presence in **Active Pharmaceutical Ingredients (API)**. Headquartered in **Vadodara, Gujarat**, the company is leveraging its significant land bank and industrial infrastructure to capitalize on the urbanization of India’s Tier II cities. --- ### Strategic Leadership & Governance Transition The company is entering a critical phase of leadership renewal aimed at driving its real estate expansion. * **New Managing Director:** **Mr. Udit Amin** has been appointed as Managing Director for a **5-year term** effective **October 1, 2025**. * **Regulatory Requirement:** As a Non-Resident Indian (**NRI**), his appointment is subject to **Central Government** approval and a shareholder special resolution. * **Executive Remuneration:** The company has established a maximum CTC of **₹10.00 Crore per annum** for key management. For FY 2023-24, a commission of **₹2.00 Crore** (**1.96% of net profits**) was approved for the Non-Executive Director. --- ### Core Business Segment: Real Estate & Urban Infrastructure Real Estate has emerged as the primary growth engine, focused on the **Alembic City** campus and the **Alembic Art District** in Vadodara. The strategy balances "for-sale" residential projects with "for-lease" commercial assets to ensure both capital appreciation and recurring revenue. #### Residential Portfolio The company targets the premium and mid-segment markets, benefiting from infrastructure tailwinds like the **Vadodara-Mumbai Expressway** and the **Delhi-Mumbai Industrial Corridor (DMIC)**. | Project Name | Segment | Status / Recent Milestone | | :--- | :--- | :--- | | **VEDA-II** | Gated Community | Completed **Q1 FY 2025**; features Vadodara’s tallest residential tower. | | **Townhouse24** | Upscale Premium | **100% sales** achieved; deliveries commenced in **FY 2023-24**. | | **The Villas** | Premium Residential | Deliveries commenced in **FY 2023-24**; steady demand. | | **The Park Crescent** | 3BHK/4BHK Residential | Recently launched; strong homebuyer interest. | | **The Gardens** | Premium Duplex | Niche launch witnessing decent demand. | #### Commercial & Mixed-Use Development Alembic is expanding its recurring income base through high-street retail, food courts, and office spaces. * **New Commercial Building:** Completion expected in **H2 FY 2025-26**; notably, **>50%** of the leasable area is already **pre-leased**. * **Strategic Collaboration:** A framework agreement exists with **Shreno Limited** for joint development in Vadodara. This involves a base consideration of **₹65.45 Crore** for **Floor Space Index (FSI)** utilization and expense reimbursements capped at **₹10 Crore per annum**. --- ### Legacy Segment: Active Pharmaceutical Ingredients (API) The API division operates **4 manufacturing plants** and **2 offices** in India. While functional, this segment faces structural headwinds. * **Operational Status:** Management describes the business as "barely sustainable" due to a **limited product portfolio**, declining prices for proprietary molecules, and low-margin job-work. * **Sustainability Investments:** Despite challenges, the company continues to invest in safety and environmental compliance. * **FY 2022-23 Total Investment:** **66.45 Lacs** (comprising **0.59 Lacs** in R&D and **65.85 Lacs** in Capex). * **Infrastructure:** Includes a **GPCB-approved Effluent Treatment Plant (ETP)** and a recently replaced **gas engine** for utility efficiency. --- ### Financial Performance & Shareholder Returns Alembic Limited maintains a robust balance sheet characterized by high growth and low debt. | Metric | FY 2024-25 (₹ Crore) | FY 2023-24 (₹ Crore) | Growth (%) | | :--- | :--- | :--- | :--- | | **Gross Revenue** | **214.36** | **152.25** | **+40.8%** | | **Net Profit** | **141.95** | **92.89** | **+52.8%** | | **Dividend per Share** | - | **₹ 2.40 (120%)** | **+9.1% (YoY)** | * **Funding Strategy:** Operations are primarily funded through **internal accruals** to maintain a strong credit rating. * **Liquidity Management:** Surplus funds are invested in **liquid securities** with high-credit-rating counterparties. * **Subsidiaries:** **Alembic City Limited** was elevated to a **material subsidiary** effective **FY 2024-25**. --- ### ESG & Operational Sustainability The company integrates environmental and social governance into its industrial and real estate operations. * **Supply Chain:** In Real Estate, **87%** of inputs are sourced locally, with **36%** from **MSMEs**. In API, **78%** of inputs are local, though key starting materials require imports. * **Green Building:** Projects utilize **recycled steel, fly ash, AAC blocks**, and include **EV charging stations**. * **Energy:** Operations utilize **wind-operated power** and solar-powered street lights. * **Safety:** Implements a **"Stop Work Policy"** and maintains an **Occupational Health Center (OHC)** with ambulance facilities. All sites undergo **100%** health and safety assessments. --- ### Risk Factors & Contingencies #### 1. Legal & Regulatory Disputes * **Electricity Duty:** A major dispute with the **State of Gujarat**. The company has provided **₹20.52 Crore** for the principal and deposited **₹35 Crore** with the **Supreme Court**. Interest remains an unquantified **contingent liability**. * **Drug Pricing:** A **₹9.99 Crore** disputed liability exists regarding **Rifampicin** pricing with the Ministry of Industry. * **Taxation:** While a **₹6.59 Crore** Income Tax dispute was resolved in the company's favor in **November 2024**, ongoing litigation persists with **Central GST/Excise** regarding property sales post-completion. #### 2. Audit & Accounting Risks * **Qualified Opinion:** The **FY 2023-24** consolidated statements received a **qualified opinion** due to an accounting treatment at associate company **Alembic Pharmaceuticals Limited (APL)**. APL transferred **₹1,025.66 Crore** from General Reserves to the P&L to preserve distributable profits—a move auditors contested. * **Related Party Transactions:** Transactions with **Shreno Limited** were projected to exceed **10% of annual consolidated turnover** (threshold: **₹15.75 Crore**), requiring specific shareholder oversight. #### 3. Market & Macroeconomic Risks * **Real Estate Volatility:** The sector faces risks from **RBI interest rate revisions**, which impact buyer affordability, and a heavy reliance on **migrant labor**. * **Geographic Concentration:** Operations are heavily concentrated in **Gujarat**, making the company sensitive to regional economic shifts. * **API Sustainability:** The high cost of modernizing the API plant versus the high value of its city-center land creates a strategic tension regarding the segment's long-term viability.